What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Surgery, Abiraterone acetate, Prostate cancer and Urology.
His work carried out in the field of Internal medicine brings together such families of science as Immunology, Gastroenterology and Oncology.
His work in Surgery addresses subjects such as Follicular lymphoma, which are connected to disciplines such as Survival rate, Radioimmunotherapy and Ibritumomab tiuxetan.
Arturo Molina regularly links together related areas like Docetaxel in his Abiraterone acetate studies.
His Prostate cancer research incorporates elements of Endocrinology and Circulating tumor cell.
His study in Urology is interdisciplinary in nature, drawing from both Androgen deprivation therapy, Apalutamide, Placebo and Performance status.
His most cited work include:
- Abiraterone and Increased Survival in Metastatic Prostate Cancer (3027 citations)
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy (1814 citations)
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study (907 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Abiraterone acetate, Oncology, Prostate cancer and Surgery.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Endocrinology.
His Abiraterone acetate study combines topics in areas such as Urology, Placebo, Androgen, Docetaxel and Prednisone.
His research in Urology tackles topics such as Orteronel which are related to areas like CYP17A1 Inhibitor and Antiandrogen.
His work in Prostate cancer tackles topics such as Circulating tumor cell which are related to areas like Cancer biomarkers.
In his study, Proportional hazards model is inextricably linked to Hazard ratio, which falls within the broad field of Surgery.
He most often published in these fields:
- Internal medicine (71.24%)
- Abiraterone acetate (41.63%)
- Oncology (41.20%)
What were the highlights of his more recent work (between 2013-2020)?
- Internal medicine (71.24%)
- Prostate cancer (38.63%)
- Abiraterone acetate (41.63%)
In recent papers he was focusing on the following fields of study:
Arturo Molina focuses on Internal medicine, Prostate cancer, Abiraterone acetate, Oncology and Prednisone.
Many of his studies involve connections with topics such as Gastroenterology and Internal medicine.
His studies deal with areas such as Endocrinology, Clinical trial and Chemotherapy as well as Prostate cancer.
Arturo Molina interconnects Surgery, Urology, Placebo, Docetaxel and Hazard ratio in the investigation of issues within Abiraterone acetate.
His studies in Surgery integrate themes in fields like Adverse effect and Confidence interval.
His Oncology research includes elements of Post-hoc analysis, Prospective cohort study, Cancer biomarkers and Circulating tumor cell.
Between 2013 and 2020, his most popular works were:
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study (712 citations)
- Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer (268 citations)
- Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302) (183 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Abiraterone acetate, Prostate cancer, Internal medicine, Oncology and Prednisone are his primary areas of study.
The various areas that Arturo Molina examines in his Abiraterone acetate study include Endocrinology, Surgery, Urology, Docetaxel and Testosterone.
In Surgery, Arturo Molina works on issues like Hazard ratio, which are connected to Survival rate and Gastroenterology.
His research investigates the connection with Prostate cancer and areas like Chemotherapy which intersect with concerns in Discontinuation and Confidence interval.
His biological study focuses on Phases of clinical research.
His Oncology research is multidisciplinary, incorporating elements of Cancer, Cancer biomarkers, Post-hoc analysis, Proportional hazards model and Prospective cohort study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
